[go: up one dir, main page]

MX2019009821A - Metodos para tratar cancer con inhibidores de farnesiltransferasa. - Google Patents

Metodos para tratar cancer con inhibidores de farnesiltransferasa.

Info

Publication number
MX2019009821A
MX2019009821A MX2019009821A MX2019009821A MX2019009821A MX 2019009821 A MX2019009821 A MX 2019009821A MX 2019009821 A MX2019009821 A MX 2019009821A MX 2019009821 A MX2019009821 A MX 2019009821A MX 2019009821 A MX2019009821 A MX 2019009821A
Authority
MX
Mexico
Prior art keywords
methods
treating cancer
farnesyltransferase inhibitors
fti
farnesyltransferase
Prior art date
Application number
MX2019009821A
Other languages
English (en)
Other versions
MX394077B (es
Inventor
Rose Scholz Catherine
Gualberto Antonio
Original Assignee
Kura Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/820,012 external-priority patent/US10137121B2/en
Application filed by Kura Oncology Inc filed Critical Kura Oncology Inc
Publication of MX2019009821A publication Critical patent/MX2019009821A/es
Publication of MX394077B publication Critical patent/MX394077B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al campo de la terapia contra el cáncer. Específicamente, se proporcionan métodos para tratar el cáncer, por ejemplo, el linfoma de células T periférico ("PTCL"), con un inhibidor de farnesiltransferasa (FTI) que incluyen determinar si el sujeto puede responder al tratamiento con FTI en función de las características de expresión génica.
MX2019009821A 2017-02-21 2018-02-21 Metodos para tratar cancer con inhibidores de farnesiltransferasa. MX394077B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762461602P 2017-02-21 2017-02-21
US201762507749P 2017-05-17 2017-05-17
US201762519819P 2017-06-14 2017-06-14
US15/820,012 US10137121B2 (en) 2017-02-21 2017-11-21 Methods of treating cancer with farnesyltransferase inhibitors
US15/820,157 US9956215B1 (en) 2017-02-21 2017-11-21 Methods of treating cancer with farnesyltransferase inhibitors
US201762596653P 2017-12-08 2017-12-08
PCT/US2018/018989 WO2018156609A1 (en) 2017-02-21 2018-02-21 Methods of treating cancer with farnesyltransferase inhibitors

Publications (2)

Publication Number Publication Date
MX2019009821A true MX2019009821A (es) 2019-12-02
MX394077B MX394077B (es) 2025-03-24

Family

ID=63253363

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009821A MX394077B (es) 2017-02-21 2018-02-21 Metodos para tratar cancer con inhibidores de farnesiltransferasa.
MX2022008843A MX2022008843A (es) 2017-02-21 2019-08-16 Metodos para tratar cancer con inhibidores de farnesiltransferasa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022008843A MX2022008843A (es) 2017-02-21 2019-08-16 Metodos para tratar cancer con inhibidores de farnesiltransferasa.

Country Status (14)

Country Link
EP (3) EP3432883B1 (es)
JP (1) JP7289795B2 (es)
KR (3) KR102138904B1 (es)
CN (4) CN109999037A (es)
AU (3) AU2018225566B2 (es)
BR (1) BR112019017375A2 (es)
CA (1) CA3053795A1 (es)
ES (2) ES2927228T3 (es)
IL (1) IL268722A (es)
MX (2) MX394077B (es)
PH (1) PH12019501918A1 (es)
SG (1) SG11201907594TA (es)
TW (3) TWI693074B (es)
WO (1) WO2018156609A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019032489A1 (en) * 2017-08-07 2019-02-14 Kura Oncology, Inc. METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS
WO2020190604A1 (en) * 2019-03-15 2020-09-24 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2025224720A1 (en) * 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5310652A (en) 1986-08-22 1994-05-10 Hoffman-La Roche Inc. Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5693517A (en) 1987-06-17 1997-12-02 Roche Molecular Systems, Inc. Reagents and methods for coupled high temperature reverse transcription and polymerase chain reactions
US5561058A (en) 1986-08-22 1996-10-01 Hoffmann-La Roche Inc. Methods for coupled high temperatures reverse transcription and polymerase chain reactions
IE72468B1 (en) 1987-07-31 1997-04-09 Univ Leland Stanford Junior Selective amplification of target polynucleotide sequences
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
IL100040A (en) 1990-11-13 1995-12-31 Siska Diagnostics Inc Nucleic acid amplification by two enzyme self-sustained sequence replication
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
CA2131543C (en) 1992-03-04 2002-09-17 Daniel Pinkel Comparative genomic hybridization
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5686472A (en) 1992-10-29 1997-11-11 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5491063A (en) 1994-09-01 1996-02-13 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
US5571673A (en) 1994-11-23 1996-11-05 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ATE272394T1 (de) 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
CN1095845C (zh) 1996-12-20 2002-12-11 "塔比法尔"有限责任公司 制取冻干的1β,10β－环氧－13－二甲基氨基－愈创－3(4)－烯－6,12－内酯盐酸盐的方法和装置
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
EP1048301A4 (en) 1998-01-16 2005-03-09 Takeda Chemical Industries Ltd COMPOSITIONS WITH DELAYED ACTIVE INGREDIENTS, PROCESS FOR THEIR PREPARATION AND THEIR USE
JP4022044B2 (ja) 1998-03-05 2007-12-12 フォーミュラ ワン アドミニストレイション リミテッド データ通信システム
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
AU5086499A (en) 1998-07-01 2000-01-24 Merck & Co., Inc. Process for making farnesyl-protein transferase inhibitors
PL193464B1 (pl) 1998-07-06 2007-02-28 Janssen Pharmaceutica Nv Zastosowanie inhibitora białkowej transferazy farnezylowej
KR20010072991A (ko) 1998-08-27 2001-07-31 실버스타인 아써 에이. 항암제로서 유용한 알키닐-치환된 퀴놀린-2-온 유도체
ES2237125T3 (es) 1998-08-27 2005-07-16 Pfizer Products Inc. Derivados de quinolin-2-ona utiles como agentes anticancerigenos.
US6927024B2 (en) 1998-11-30 2005-08-09 Genentech, Inc. PCR assay
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001042507A1 (en) 1999-12-09 2001-06-14 Advanced Research & Technology Institute Fluorescent in situ rt-pcr
ES2293972T3 (es) 2000-02-24 2008-04-01 Janssen Pharmaceutica N.V. Regimen de dosificacion que comprende un inhibidor de la farnesil proteina transferasa para el tratamiento del cancer.
US7101663B2 (en) 2001-03-02 2006-09-05 University of Pittsburgh—of the Commonwealth System of Higher Education PCR method
US7122799B2 (en) 2003-12-18 2006-10-17 Palo Alto Research Center Incorporated LED or laser enabled real-time PCR system and spectrophotometer
WO2006036892A2 (en) * 2004-09-24 2006-04-06 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
US20070093449A1 (en) * 2005-10-14 2007-04-26 De Porre Peter M R Novel IV formulation of tipifarnib
CN102216332A (zh) * 2008-10-31 2011-10-12 艾伯特生物治疗学公司 抗-cs1抗体用于治疗罕见淋巴瘤的用途
JP2012516354A (ja) * 2009-01-30 2012-07-19 ジェンザイム・コーポレーション 乳癌を治療するための方法及び組成物
WO2012016021A2 (en) * 2010-07-28 2012-02-02 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
EP2476441A1 (en) * 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells
JP6541350B2 (ja) * 2011-11-09 2019-07-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｃｘｃｒ４抗体による血液悪性腫瘍の処置
CN103787907B (zh) * 2014-02-17 2015-05-27 华东理工大学 作为法尼基转移酶抑制剂的苯胺类化合物及其用途
WO2017184968A1 (en) * 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors

Also Published As

Publication number Publication date
TWI738314B (zh) 2021-09-01
TW201929903A (zh) 2019-08-01
ES2892157T3 (es) 2022-02-02
TWI663974B (zh) 2019-07-01
BR112019017375A2 (pt) 2020-03-31
CN109999037A (zh) 2019-07-12
KR102138904B1 (ko) 2020-07-28
SG11201907594TA (en) 2019-09-27
CN109475550A (zh) 2019-03-15
ES2927228T3 (es) 2022-11-03
JP7289795B2 (ja) 2023-06-12
TW202031260A (zh) 2020-09-01
EP3542800B1 (en) 2022-06-01
KR20200090982A (ko) 2020-07-29
EP3432883B1 (en) 2021-07-28
AU2018225566A1 (en) 2018-11-08
CN114712354A (zh) 2022-07-08
JP2020508351A (ja) 2020-03-19
KR20190087661A (ko) 2019-07-24
EP3542800A1 (en) 2019-09-25
AU2018225566B2 (en) 2019-11-07
TWI693074B (zh) 2020-05-11
AU2019246922A1 (en) 2019-10-31
EP4119142A1 (en) 2023-01-18
MX2022008843A (es) 2022-08-10
AU2019203548A1 (en) 2019-06-13
CN114796218A (zh) 2022-07-29
IL268722A (en) 2019-10-31
CA3053795A1 (en) 2018-08-30
EP3432883A1 (en) 2019-01-30
TW201834652A (zh) 2018-10-01
PH12019501918A1 (en) 2020-06-01
MX394077B (es) 2025-03-24
KR102003179B1 (ko) 2019-07-23
KR20180123723A (ko) 2018-11-19
AU2019203548C1 (en) 2020-01-23
WO2018156609A1 (en) 2018-08-30
AU2019203548B2 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
BR112018000542A2 (pt) composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr
MX391815B (es) AGENTES DE iARN, COMPOSICIONES Y METODOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON TRANSTITERINA (TTR).
CL2018001591A1 (es) Compuestos útiles como inhibidores de cinasa.-
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
BR112019006876A2 (pt) anticorpos e composições anti-lag-3
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
BR112017000130A2 (pt) método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
MX2017010773A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer.
WO2018098117A8 (en) SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
MX2020006297A (es) Variantes de cd19.
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
JO3558B1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
MX2022008843A (es) Metodos para tratar cancer con inhibidores de farnesiltransferasa.
JOP20210158A1 (ar) مُعَدِّلات التعبير الجيني عن hsd17b13
MX2018003301A (es) Inhibidores de pcna.
MX2019005065A (es) Metodos de tratamiento de pacientes con cancer con inhibidores de farnesiltransferasa.
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
MX2020009147A (es) Moduladores de la expresion de irf4.
MA40607B1 (fr) Traitements médicaux à base d'anamoréline
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.